Advertising

Confusing Risk Information Leads To Poor Cancer Treatment Choices

Advertisement
2008-12-09 09:00

A new study from researchers at the University of Michigan Comprehensive Cancer Center found that a tool commonly used by doctors to estimate the risk of a woman's breast cancer returning after surgery is not very effective at explaining risk to patients. As a result, women with breast cancer may not find these tools helpful when deciding whether to have chemotherapy.

The tool itself is very useful to doctors, many of whom print out information from this tool and give it to patients when they are discussing chemotherapy. Nearly all women diagnosed with early stage breast cancer will have surgery, but many will also consider chemotherapy to help prevent the cancer from coming back.

"The main benefit of additional treatments such as chemotherapy after surgery is long-term risk reduction. But chemotherapy does not provide much benefit for some women, and those women can potentially avoid unnecessary side effects by skipping chemotherapy. So understanding how large or small the risk reduction is can help women make the right choice," says lead study author Brian Zikmund-Fisher, Ph.D., research assistant professor of general medicine at the U-M Medical School and a researcher at the VA Ann Arbor Healthcare System.

The currently available risk-assessment tools present risk statistics in a bar graph format that compares four different potential choices: hormonal therapy alone, chemotherapy alone, both hormonal and chemotherapy, or no treatment at all. The problem, Zikmund-Fisher points out, is that most women are really only choosing between two options: For women whose cancers are sensitive to the hormone estrogen, hormonal treatments provide large benefits with few side effects. The real question is whether chemotherapy is also necessary.

Advertisement

Because the tool shows statistics about all four options, however, the researchers found that it is more difficult for women to find and focus on the number that most matters to their choice: the benefit of adding chemotherapy to hormonal therapy.

Pages

Advertisement
Subscribe to EmaxHealth on YouTube

Comments

It's not a question of doctors spending as little time as possible explaining the numbers to patients. Discussions of risk need to be as thoroughly thought out and presented as much as possible. That is the best way to make sure that each patient can make the right choice for their situation. Informing cancer patients of the benefits and risks specific to a new or existing medicine helps ensure patients are safely and effectively treated. A trusting partnership between doctor and patient that facilitates informed consent is a goal for many proactive patients. Such a partnership requires an understanding of all the factors that lead to a treatment recommendation. In light of the precious little in the way of guidance from clinical trials with respect to best empiric treatment, which is based on medical journal articles, epidemiology and economics, a patient's decision based on risk information will incorporate better understanding. Gregory D. Pawelski
It's is all in the presentation. When no alternatives are presented, people will tend to seize what is available. When relative risk numbers that really do not relate to actual risk are given, it makes informed decision making even more difficult. The method used to present information about chemotherapy influences treatment decisions. In deciding on endorsing chemotherapy, patients understand the information best when presented with data in the absolute survival benefit format, rather than those presented with data in the relative risk reduction information format. Absolute survival benefit is the most easily understood method of conveying the information regarding benefit of treatment. Discussions between doctors and patients about the risks and benefits of chemotherapy need to be changed. Being told that chemotherapy reduces your risk by 30% of recurrence can be misleading and meaningless, unless you know your risk in the first place. If your risk of recurrence is 15%, you are only reducing it by 5%. And this doesn't even reflect the harm that could be done to those who don't need the treatment. What is that harm? There are the toxicities that can end your life: leukemia and heart failure. There are toxicities that can ruin your life: loss of libido, loss of cognitive function, severe joint pain, and bone fractures. These harms are usually ignored or understated. One of the reasons is because they are understudied. Source: Journal of Clinical Oncology, Vol 21, Issue 23 (December), 2003: 4299-4305

Pages